Bioglan will manufacture LECIGON® for Lobsor Pharmaceuticals
- LECIGON® is a newly developed proprietary pharmaceutical treatment of advanced Parkinson’s disease
- Bioglan will be the exclusive manufacturer for the European market
Bioglan, the Swedish subsidiary of the Spanish pharmaceutical company Reig Jofre, has now signed an agreement with Lobsor Pharmaceuticals for the exclusive manufacturing of LECIGON®, a medicine used for the treatment of advanced Parkinson’s disease.
Bioglan, a specialized pharmaceutical manufacturer and Lobsor Pharmaceuticals, specialty pharmaceutical company focused on innovative, proprietary technologies and drug formulations for the treatment of Parkinson’s disease, announced the manufacturing collaboration of LECIGON®.
This agreement implies the expansion of Bioglan’s facilities, to meet the quality systems and the productive needs of Lobsor Pharmaceuticals. The investment dedicated to the installation of a fourth semi-solid production line amounts to 1 million euros.